- Home
- FORTY vs RCUS Comparison
FORTY vs RCUS Comparison
Compare FORTY & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FORTY
- RCUS
- Stock Information
- Founded
- FORTY 1985
- RCUS 2015
- Country
- FORTY Israel
- RCUS United States
- Employees
- FORTY N/A
- RCUS N/A
- Industry
- FORTY EDP Services
- RCUS Biotechnology: Pharmaceutical Preparations
- Sector
- FORTY Technology
- RCUS Health Care
- Exchange
- FORTY Nasdaq
- RCUS Nasdaq
- Market Cap
- FORTY 1.3B
- RCUS 1.4B
- IPO Year
- FORTY 1997
- RCUS 2018
- Fundamental
- Price
- FORTY $87.78
- RCUS $14.02
- Analyst Decision
- FORTY
- RCUS Buy
- Analyst Count
- FORTY 0
- RCUS 12
- Target Price
- FORTY N/A
- RCUS $34.50
- AVG Volume (30 Days)
- FORTY 465.0
- RCUS 609.3K
- Earning Date
- FORTY 03-18-2025
- RCUS 02-19-2025
- Dividend Yield
- FORTY 1.41%
- RCUS N/A
- EPS Growth
- FORTY 18.72
- RCUS N/A
- EPS
- FORTY 4.83
- RCUS N/A
- Revenue
- FORTY $2,706,303,000.00
- RCUS $263,000,000.00
- Revenue This Year
- FORTY N/A
- RCUS $127.65
- Revenue Next Year
- FORTY N/A
- RCUS N/A
- P/E Ratio
- FORTY $17.86
- RCUS N/A
- Revenue Growth
- FORTY 2.60
- RCUS 119.17
- 52 Week Low
- FORTY $60.39
- RCUS $13.51
- 52 Week High
- FORTY $96.50
- RCUS $20.31
- Technical
- Relative Strength Index (RSI)
- FORTY 49.62
- RCUS 37.13
- Support Level
- FORTY $80.15
- RCUS $13.81
- Resistance Level
- FORTY $88.20
- RCUS $14.52
- Average True Range (ATR)
- FORTY 0.94
- RCUS 0.60
- MACD
- FORTY -0.34
- RCUS -0.09
- Stochastic Oscillator
- FORTY 57.80
- RCUS 22.97
About FORTY Formula Systems (1985) Ltd.
Formula Systems (1985) Ltd is a holding company that, through its subsidiaries, provides information technology services. The company organizes itself into operating segments: The Matrix segment, which generates the majority of revenue, provides software development and existing software expansion services. The Sapiens segment provides software development services for the insurance industry. The Magic Software segment provides vendor management systems and workforce management services, which include accounting and finance, human resources; Michpal; ZAP Group and Others. The majority of the company's revenue comes from Israel.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.